News
AceLink’s AL01211, an oral GCS inhibitor, completed six-month Phase 2 in Fabry disease. Results show good safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback